EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)

摘要-早期临床研究支持(EPCRS) 早期临床研究支持(EPCRS)为创新的短期提供关键资源 在北卡罗来纳大学莱恩伯格综合癌症中心(LCCC)以熟练和 专门的研究协调员、数据管理和实验室支持。由该公司支持的试验 来源：与科学和/或药代动力学和药效学有很强相关性的复合体 组成部分；LCCC调查员发起；主要基于LCCC的科学专业知识和兴趣 会员。试验是从提交给礼宾办公室执行委员会的试验中挑选出来的 复习一下。克莱尔·迪斯博士，EPCRS教研室主任兼临床研究计划联合负责人，直接 咨询Carey博士(临床科学部副主任)和Hayes博士(临床研究联席主管 程序)，进行最终选择。LCCC成员在过去五年中进行了大量创新研究 年，包括：用辐射评价新化合物；涉及新组合；以及 结合新的相关生物标志物和成像。许多ECPRS支持的试验起源于基础和 北卡罗来纳大学莱恩伯格实验室的临床前科学。 自2010年以来，LCCC招募了一批有才华的调查员，积极发展我们的第一阶段调查员 启动了试验组合，因此我们预计将扩大ECPRS的使用。此外，北卡罗来纳大学的首场审判 免疫治疗中心将在这个周期开始，并需要额外的专业支持。首批患者 将在2016年春季登记参加北卡罗来纳大学的免疫疗法试验，这些初步试验将包括患者 患有急性淋巴细胞白血病、慢性淋巴细胞白血病、霍奇金淋巴瘤和多发性骨髓瘤。 北卡罗来纳州莱恩伯格大学领导层对开发新疗法的坚定承诺 癌症中心的战略方向创造了一个环境，将产生更大的需求 专业支持。

Abstract - Early Phase Clinical Research Support (EPCRS) The Early Phase Clinical Research Support (EPCRS) provides critical resources for innovative short duration research protocols at UNC Lineberger Comprehensive Cancer Center (LCCC) in the form of skilled and specialized research coordinator, data management, and laboratory support. The trials supported by this resource are: complex with strong correlative science and/or pharmacokinetic and pharmacodynamic components; LCCC investigator-initiated; and primarily based on scientific expertise and interests of LCCC members. Trials are selected from among those submitted to the Protocol Office Executive Committee for review. Dr Claire Dees, EPCRS Faculty Director and co-leader, Clinical Research Program, in direct consultation with Drs. Carey (Associate Director, Clinical Sciences) and Hayes (co-leader, Clinical Research Program), makes the final selection. LCCC members conducted numerous innovative studies over the last five years including those: evaluating novel compounds with radiation; involving novel combinations; and incorporating novel correlative biomarkers and imaging. Many ECPRS supported trials originated in basic and preclinical science in UNC Lineberger laboratories. Since 2010, LCCC recruited a number of talented investigators actively growing our Phase I investigator initiated trial portfolio and so we anticipate expanded ECPRS use. In addition, the inaugural trials of the UNC immunotherapy center will begin in this cycle and will require additional specialized support. The first patients will be enrolled on UNC immunotherapy trials in the spring of 2016 and these initial trials would include patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and multiple myeloma. The strong commitment of the UNC Lineberger leadership to the development of novel therapeutics as a Cancer Center strategic direction creates an environment that will generate even greater demand for specialized support.